Chelsea Therapeutics (NASDAQ:CHTP) left investors stunned today after taking a steep tumble. Shares dropped almost 30% after the Food and Drug Administration (FDA) posted briefing documents ahead of an advisory committee meeting for Chelsea's drug Northera. The meeting is scheduled for next week, but what did the market see in today's release? Analysts David Williamson and Max Macaluso discuss the details in the video below.
David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.